157 related articles for article (PubMed ID: 17073766)
21. Hormonal therapy for prostate cancer: toward further unraveling of androgen receptor function.
Sharifi N
Anticancer Agents Med Chem; 2009 Dec; 9(10):1046-51. PubMed ID: 19719456
[TBL] [Abstract][Full Text] [Related]
22. UHRF1 promotes androgen receptor-regulated CDC6 transcription and anti-androgen receptor drug resistance in prostate cancer through KDM4C-Mediated chromatin modifications.
Gao Y; Liu Y; Liu Y; Peng Y; Yuan B; Fu Y; Qi X; Zhu Q; Cao T; Zhang S; Yin L; Li X
Cancer Lett; 2021 Nov; 520():172-183. PubMed ID: 34265399
[TBL] [Abstract][Full Text] [Related]
23. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
24. Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment.
Marques RB; Erkens-Schulze S; de Ridder CM; Hermans KG; Waltering K; Visakorpi T; Trapman J; Romijn JC; van Weerden WM; Jenster G
Int J Cancer; 2005 Nov; 117(2):221-9. PubMed ID: 15900601
[TBL] [Abstract][Full Text] [Related]
25. Androgen receptor as a target in androgen-independent prostate cancer.
Balk SP
Urology; 2002 Sep; 60(3 Suppl 1):132-8; discussion 138-9. PubMed ID: 12231070
[TBL] [Abstract][Full Text] [Related]
26. Altered corepressor SMRT expression and recruitment to target genes as a mechanism that change the response to androgens in prostate cancer progression.
Godoy AS; Sotomayor PC; Villagran M; Yacoub R; Montecinos VP; McNerney EM; Moser M; Foster BA; Onate SA
Biochem Biophys Res Commun; 2012 Jul; 423(3):564-70. PubMed ID: 22695118
[TBL] [Abstract][Full Text] [Related]
27. Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells.
Dehm SM; Tindall DJ
J Biol Chem; 2006 Sep; 281(38):27882-93. PubMed ID: 16870607
[TBL] [Abstract][Full Text] [Related]
28. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
[TBL] [Abstract][Full Text] [Related]
29. Targeting the androgen receptor.
Friedlander TW; Ryan CJ
Urol Clin North Am; 2012 Nov; 39(4):453-64. PubMed ID: 23084523
[TBL] [Abstract][Full Text] [Related]
30. Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
Mostaghel EA; Nelson PS; Lange P; Lin DW; Taplin ME; Balk S; Ellis W; Kantoff P; Marck B; Tamae D; Matsumoto AM; True LD; Vessella R; Penning T; Hunter Merrill R; Gulati R; Montgomery B
J Clin Oncol; 2014 Jan; 32(3):229-37. PubMed ID: 24323034
[TBL] [Abstract][Full Text] [Related]
31. Transcriptional suppression of androgen receptor by 18β-glycyrrhetinic acid in LNCaP human prostate cancer cells.
Sun Y; Jiang M; Park PH; Song K
Arch Pharm Res; 2020 Apr; 43(4):433-448. PubMed ID: 32219716
[TBL] [Abstract][Full Text] [Related]
32. The androgen receptor in hormone-refractory prostate cancer.
Mao HL; Zhu ZQ; Chen CD
Asian J Androl; 2009 Jan; 11(1):69-73. PubMed ID: 19050686
[TBL] [Abstract][Full Text] [Related]
33. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
[TBL] [Abstract][Full Text] [Related]
34. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.
Lin TH; Izumi K; Lee SO; Lin WJ; Yeh S; Chang C
Cell Death Dis; 2013 Aug; 4(8):e764. PubMed ID: 23928703
[TBL] [Abstract][Full Text] [Related]
35. The complex role of AR signaling after cytotoxic insult: implications for cell-cycle-based chemotherapeutics.
Comstock CE; Knudsen KE
Cell Cycle; 2007 Jun; 6(11):1307-13. PubMed ID: 17568191
[TBL] [Abstract][Full Text] [Related]
36. Structure-based virtual screening and identification of a novel androgen receptor antagonist.
Song CH; Yang SH; Park E; Cho SH; Gong EY; Khadka DB; Cho WJ; Lee K
J Biol Chem; 2012 Aug; 287(36):30769-80. PubMed ID: 22798067
[TBL] [Abstract][Full Text] [Related]
37. Molecular pathogenesis and progression of prostate cancer.
Schrecengost R; Knudsen KE
Semin Oncol; 2013 Jun; 40(3):244-58. PubMed ID: 23806491
[TBL] [Abstract][Full Text] [Related]
38. The androgen receptor in prostate cancer: therapy target in search of an integrated diagnostic test.
Ross JS
Adv Anat Pathol; 2007 Sep; 14(5):353-7. PubMed ID: 17717436
[TBL] [Abstract][Full Text] [Related]
39. Antiandrogens in prostate cancer endocrine therapy.
Culig Z; Bartsch G; Hobisch A
Curr Cancer Drug Targets; 2004 Aug; 4(5):455-61. PubMed ID: 15320720
[TBL] [Abstract][Full Text] [Related]
40. Human prostatic cell line PNT1A, a useful tool for studying androgen receptor transcriptional activity and its differential subnuclear localization in the presence of androgens and antiandrogens.
Avancès C; Georget V; Térouanne B; Orio F; Cussenot O; Mottet N; Costa P; Sultan C
Mol Cell Endocrinol; 2001 Nov; 184(1-2):13-24. PubMed ID: 11694337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
